NEW YORK — Laboratory Corporation of America and NowDiagnostics (NowDx) said Tuesday that they have launched an initiative to distribute NowDx's First to Know Syphilis test at no cost to ...

The acquisition was opposed by some Quanterix shareholders. In May, Akoya also said it received an unsolicited acquisition bid for the firm.

The test is used for the detection of antibodies against Borrelia burgdorferi in serum from patients with signs, symptoms, and clinical history consistent with Lyme disease.

Cardio Dx will sponsor a clinical study investigating use of its PrecisionCHD test to identify patients with CHD and assess response to Agepha's low-dose colchicine agent LODOCO.

The acquired antibodies target hormones like thyroid stimulating hormone, human chorionic gonadotropin, prolactin, and total thyroxine.